Vaxcyte, Inc.PCVX

Vaxcyte, Inc. is a clinical-stage biopharmaceutical company headquartered at 825 Industrial Road, San Carlos, California, that is developing antibiotics designed to address the growing threat of antibiotic-resistant infections. The company’s latest 10-Q, filed for the quarter ended 31 March 2026, shows a company haemorrhaging cash at scale: net loss attributable to parent of $-320.6 million, operating loss of $-345.9 million, and negative operating cash flow of $-280.6 million. Revenue is not disclosed in the filing, which underscores that Vaxcyte remains pre-commercial and reliant on external financing to sustain operations. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1649094/000095012326000108/pcvx-20260331.htm)

What Vaxcyte does is real enough: it is building a pipeline of novel antibiotics aimed at infections that no longer respond to existing drugs. The problem is that the filings make clear this work is still in the R&D phase. The company spent $312.8 million on R&D in the quarter, about 98% of its operating expenses, while generating no revenue. The balance sheet shows $3.35 billion of assets, but $1.48 billion of that is short-term investments-hardly the kind of liquid runway you’d expect from a company that claims to be on the cusp of transformational antibiotics. Shareholders’ equity stands at $3.00 billion, but that figure is more a function of accounting than of operating performance. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1649094/000095012326000108/pcvx-20260331.htm)

Vaxcyte’s most recent 10-Q for 31 March 2026 lays out the hard numbers: net income attributable to parent of $-320.6 million, operating income of $-345.9 million, diluted EPS of $-2.30, and weighted average diluted shares of 139.5 million. Cash and equivalents were $260.8 million at quarter-end, short-term investments $1.48 billion, and net cash used in operating activities $-280.6 million. Capital expenditure was a trifling $2.1 million-hardly a sign of a company scaling manufacturing or commercial infrastructure. The filings do not break out revenue by product or geography, because none exists yet. (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1649094/000095012326000108/pcvx-20260331.htm)

The company’s most recent SEC activity has been administrative rather than developmental. An 8-K filed on 15 July 2026 is simply an address confirmation at 825 Industrial Road, San Carlos. Two earlier 8-Ks, on 16 and 23 June 2026, do the same. These filings are procedural, not product or financial catalysts, and they underscore how thin the evidence is when it comes to near-term revenue, approvals, or partnerships. For now, the market is left to trade on the promise of a pipeline while the filings continue to speak in red ink and unproven science. (source: SEC EDGAR 8-K, https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/pcvx-20260713.htm)

Vaxcyte’s story is one of a promising science parked in a company still waiting for its first commercial act. The balance sheet looks robust on paper, but only because $1.48 billion of it is parked in short-term investments rather than generating operating cash. The board and executives have been active in filing insider transactions, including Rule 144 filings in July 2026, which-given the lack of revenue and the cash burn-invites questions about alignment between management incentives and the long runway still ahead. (source: SEC EDGAR 144 filing, https://www.sec.gov/Archives/edgar/data/1649094/000196922326000761/xsl144X01/primary_doc.xml)

What remains unproven is whether Vaxcyte’s antibiotics will reach the market, at what cost, and on what timeline. The filings do not provide revenue guidance, product revenue, or commercial milestones. Until the company can translate its R&D spend into either clinical data with a clear path to approval or a partnership with a commercial partner, the gap between the pitch and the P&L will remain the only thing shareholders can reliably trade. (source: SEC EDGAR company facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001649094.json)